| A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity S Khan, X Zhang, D Lv, Q Zhang, Y He, P Zhang, X Liu, D Thummuri, ... Nature medicine 25 (12), 1938-1947, 2019 | 401 | 2019 |
| Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity Y He, X Zhang, J Chang, HN Kim, P Zhang, Y Wang, S Khan, X Liu, ... Nature communications 11 (1), 1996, 2020 | 181 | 2020 |
| DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas Y He, R Koch, V Budamagunta, P Zhang, X Zhang, S Khan, D Thummuri, ... Journal of hematology & oncology 13, 1-13, 2020 | 75 | 2020 |
| Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity D Lv, P Pal, X Liu, Y Jia, D Thummuri, P Zhang, W Hu, J Pei, Q Zhang, ... Nature communications 12 (1), 6896, 2021 | 74 | 2021 |
| Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity X Zhang, D Thummuri, X Liu, W Hu, P Zhang, S Khan, Y Yuan, D Zhou, ... European journal of medicinal chemistry 192, 112186, 2020 | 72 | 2020 |
| Utilizing PROTAC technology to address the on-target platelet toxicity associated with inhibition of BCL-XL X Zhang, D Thummuri, Y He, X Liu, P Zhang, D Zhou, G Zheng Chemical Communications 55 (98), 14765-14768, 2019 | 62 | 2019 |
| Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines X Zhang, Y He, P Zhang, V Budamagunta, D Lv, D Thummuri, Y Yang, ... European journal of medicinal chemistry 199, 112397, 2020 | 42 | 2020 |
| Proteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells R Kolb, U De, S Khan, Y Luo, MC Kim, H Yu, C Wu, J Mo, X Zhang, ... Nature communications 12 (1), 1281, 2021 | 36 | 2021 |
| Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL–Specific Degrader DT2216 D Thummuri, S Khan, PW Underwood, P Zhang, J Wiegand, X Zhang, ... Molecular cancer therapeutics 21 (1), 184-192, 2022 | 34 | 2022 |
| Discovery of a Novel BCL-XL PROTAC Degrader with Enhanced BCL-2 Inhibition P Pal, D Thummuri, D Lv, X Liu, P Zhang, W Hu, SK Poddar, N Hua, ... Journal of medicinal chemistry 64 (19), 14230-14246, 2021 | 30 | 2021 |
| BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers S Khan, J Wiegand, P Zhang, W Hu, D Thummuri, V Budamagunta, N Hua, ... Journal of Hematology & Oncology 15 (1), 23, 2022 | 29 | 2022 |
| (−)-Meptazinol–melatonin hybrids as novel dual inhibitors of cholinesterases and amyloid-β aggregation with high antioxidant potency for Alzheimer’s therapy S Cheng, W Zheng, P Gong, Q Zhou, Q Xie, L Yu, P Zhang, L Chen, J Li, ... Bioorganic & Medicinal Chemistry 23 (13), 3110-3118, 2015 | 27 | 2015 |
| PROTACs are effective in addressing the platelet toxicity associated with BCL-XL inhibitors P Zhang, X Zhang, X Liu, S Khan, D Zhou, G Zheng Exploration of targeted anti-tumor therapy 1 (4), 259, 2020 | 18 | 2020 |
| Targeting BCL-XL in fibrolamellar hepatocellular carcinoma B Shebl, D Ng, G Lalazar, C Rosemore, TM Finkelstein, RD Migler, ... JCI insight 7 (17), 2022 | 13 | 2022 |
| Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells Y Jia, L Han, CL Ramage, Z Wang, CC Weng, L Yang, S Colla, H Ma, ... Haematologica 108 (10), 2626, 2023 | 11 | 2023 |
| Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice S Khan, P Kellish, N Connis, D Thummuri, J Wiegand, P Zhang, X Zhang, ... Cell Death Discovery 9 (1), 1, 2023 | 8 | 2023 |
| Deuteration of the farnesyl terminal methyl groups of δ-tocotrienol and its effects on the metabolic stability and ability of inducing G-CSF production X Liu, Z Gao, Q Fu, L Song, P Zhang, X Zhang, H Hendrickson, PA Crooks, ... Bioorganic & medicinal chemistry 28 (11), 115498, 2020 | 8 | 2020 |
| Patent landscape of inhibitors and PROTACs of the anti-apoptotic BCL-2 family proteins P Pal, P Zhang, SK Poddar, G Zheng Expert opinion on therapeutic patents 32 (9), 1003-1026, 2022 | 7 | 2022 |
| Targeting BCL-XL and BCL-2 by protac 753B effectively eliminates AML cells and enhances efficacy of chemotherapy by targeting senescent cells Y Jia, Q Zhang, W Zhang, M Andreeff, N Jain, P Zhang, G Zheng, D Zhou, ... Blood 138, 2230, 2021 | 7 | 2021 |
| Compositions targeting senescent cells and the uses thereof D Zhou, G Zheng, X Zhang, Y Wang, J Chang, F Xia, MS De Almeida, ... US Patent App. 16/165,797, 2019 | 6 | 2019 |
Guangrong ZhengProfessor, University of FloridaVerified email at cop.ufl.edu
